Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q1 FY25 Earnings Presentation
39 slides from Blue Jet Healthcare's earnings presentation, Aug 6, 2024
Slide 1: Exchange filing cover letter: Analysts/Investors Presentation
@ BLUE JET HEALTHCARE LIMITED REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA, PLOT 1 &2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705 BLUE JET T : 022- 41840550 / 40037603 F: +9122 27814204 REATHRARR E : sales@bluejethealthcare.com | CIN NO. : U99999MH1968PLC014154 August 06, 2024 To, BSE Limi
Slide 2: Investor Presentation Q1FY25
@ BLUEJET HEALTHCARE Investor Presentation Q1FY25
Slide 3: Disclaimer
Disclaimer @ The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Table of Content
(@ BLUEJET HEALTHCARE Sasllins s ® 6 06 06 00O Table of Content Q1 FY25 Financials Company at a Glance « _' 7 B Contrast Media Intermediates .@ o~ High Intensity Sweeteners : Pharma Intermediates & API R&D Capabilities Growth Strategy Management and Board of Directors ® 6 06 0O 0 OO 00 Investment Ra
Slide 5: Q1 FY25 Financials
(0)4] Q1 FY25 Financials
Slide 6: Q1 FY25 Earnings Highlights
Q1 FY25 Earnings Highlights Financial Highlights Revenue from operations for Q1 FY25 stood at Rs. 1,629 mn which de-grew 9.3% on YoY basis compared to Rs. 1,795 mnin Q1 FY24. Gross Margin improved 2% in Q1 FY25 (55% in Q1FY25 vs 53% in Q4FY24). This was due to change in Product Mix during June 24. E
Slide 7: Q1 FY25 Vs Q1 FY24 Financial Performance — Key Metrics
Q1 FY25 Vs Q1 FY24 Financial Performance — Key Metrics ‘ -~ O Revenue from Operations— Growth Trends [ERYs YoY . (49.9%) Eammmmmd (12.9%) Bl 536.8% |l 417.9% [t (9.4%) mQ1FY24 mQ1FY25 1,787 1,618 1,286 645 602 402 350 — Contrast media intermediates High-intensity sweetners Pharma intermediates and A
Slide 8: FY24 Vs FY23 Financial Performance - Key Metrics
FY24 Vs FY23 Financial Performance - Key Metrics Revenue from Operations— Growth Trends R YoY - (5.3%) Bl (27.1%) [l 178.8% |eammmmml 245.9% |[emmm (1.4%) mFY23 mFY24 7,185 7,083 5,070 4,799 1,759 1,282 340 947 — Contrast media intermediates High-intensity sweetners Pharma intermediates and API| Oth
Slide 9: Profit and Loss Statement
Profit and Loss Statement (&) Particulars (Rs. Mn) Q1FY25 Q1FY24 YoY Q4FY24 QoQ Revenue from Operations 1,629 1,795 -9.3% 1,839 -11.4% Cost Of Goods Sold 738 792 860 Gross Profit 891 1,003 -11.2% 980 -9.1% Gross Margin 54.7% 55.9% 53.3% Employee benefits expenses 148 127 141 Other expenses 300 286 3
Slide 10: Financial Performance over the years — Key Metrics
Financial Performance over the years — Key Metrics @ N— —— -~ Revenue from Operations — Growth Trends (Rs Mn) mFY21 WFY22 WFY23 wFY24 6,768 7185 7,084 4,778 5,070 4,799 4,942 3,536 1,759 . I I —~1 g 0 | i —— 418 412 3a0 ¥ : 133 3 16 55 I Contrast media intermediates High-intensity sweetners Pharma i
Slide 11: Financials for the last four years
Financials for the last four years @ N—— Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities I. Assets Revenue from Operations 4,989 6,835 7,210 7,116 Property, plant and equipment 1,188 1,185 1,282 1,492 Other Income 89 194 240 289 Other non-current assets 275 466 688 2
Slide 12: Shareholder Information
Shareholder Information Shareholding as on 30'" June 2024 Share Information as on 30t June 2024 NSE Ticker BLUEJET MF BSE Ticker 544009 OtherDlls 1.1% Market Cap (INR Cr) 7007 % free-float 14% Free-float market cap (INR Cr) 981 Cash & Cash Equivalents + Treasury 3781 Investment (INR Mn) ’ Shares Out
Slide 13: Company at a Glance
2 < Company ata Glance
Slide 14: Our Journey
Our Journey « Established Jet Chemicals « Began manufacturing high- « Enteredthe X-ray contrast Private Limited with Shahad intensity sweeteners- media sector, with a basic facility (Unit 1) saccharinand its salts building block (5- NIPA) » Commenced semi- automated manufactul . 5 « EstablishedBlue
Slide 15: Who we are
Who we are 0 A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration Development, Manufacturing” to CDMO business.
Slide 16: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance © [ aw Commercialized product 1,020.90 kL reaction capacity across ) ( INR7,115.99 mn Revenue (FY24) (12.6% INR2,292.30 mn EBITDA (FY24) (32.2% portfolio (FY24) 3 facilities (FY24) FY21-24 CAGR) margin) Key metrics ( ) ( W ( 5.13x ) ( NR 3,351.94 mn W 26.01% 21.45% Fi
Slide 17: Overview of our Product Categories
Overview of our Product Categories Contrast Media High Intensity Pharma Intermediates Intermediates Sweeteners & APIs m Contrastmediaare agents used in medical m High-intensitysweetener businessinvolves m Collaboration withinnovator pharmaceutical companies and multi-nationalgeneric imagingto enhanc
Slide 18: Contrast Media Intermediates
03 Contrast Media Intermediates
Slide 19: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers @ What s contrast media? Types of contrast media B Chemical agents that enhances the contrast of an imaging B X-ray / Computed Tomography (CT) contrast agents: lodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast media a
Slide 20: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Highly concentrated and dominated by multi-national corporations Player 1 17% Total value US$5.9bn Collectively hold ~75% of the global sales of contrast (MAT Jun 2023) media formulations’ Player 3 27% Either forward integrated (have equipmen
Slide 21: High entry barriers for key intermediates' vendors
High entry barriers for key intermediates’ vendors ‘/ . More than two decades of experience CAG 0.7% S v’ 75%+ of exports of a selected contrast media Strict internal standards intermediate (5-Amino-N,N'-bis (2,3- Revenue (INRmn) for product impurity / dihydroxypropyl) isophthalamide) from India’ +
Slide 22: Continue to forward integrate into more advanced intermediates for Contrast Media
Continue to forward integrate into more advanced intermediates for Contrast Media Strong product developmentand process optimization capabilities underpinned by in-house R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in eit
Slide 23: High Intensity Sweeteners
0)41 High Intensity Sweeteners
Slide 24: Blue Jet's positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener @ Blue Jet's positioning High Intensity Sweeteners product category performance Products /* Adherence to strict internal standards to ensure consistency in quality, performance, | CAG 1% @ taste, and impurity profile Revenue (INRmn) Multiple product
Slide 25: Pharma Intermediates & API
05 Pharma Intermediates & API
Slide 26: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product @ Category Key trends in Pharma Intermediates and CDMO market . . . N Revenue and capacity utilization predictability Increased propensity to outsource manufacturing of intermediates & APIs for the CDMO Ena-hles asset light model and a
Slide 27: Overview of Blue Jet's Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product @ Category ) Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity e B [ e @ sweetenerbusiness g& Key focus areas include high-value pharma intermediates and APIs CAGR: 3
Slide 28: Leverage long-standing customer relationships to enter adjacencies in pharma intermediates and API
Leverage our long-standing customer relationships to continue @ entering adjacencies in the pharma intermediate and API category Focus on three niche areas in providing CDMO services Blue Jet’s positioning 7N\ 7N\ ' Investigational new drugs and new chemical Leverage long-standing relationships with
Slide 29: R&D Capabilities
06 73 R&D Capabilities ’Q/C
Slide 30: Our R&D framework
Our R&D framework @ R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research ( ] ( Method ] ( Characterization of w ( Polymorphism w (Pharmaceuticalsaltw ( w ( High pressu
Slide 31: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW ——— Created carbon sinks Focus on enhancing through tree plantations energy efficiency ) — Effluent treatment plants wit
Slide 32: Growth Strategy
0/ 73 Growth Strategy ’Q/C
Slide 33: Our strategies
Our strategies (&) PO ( h Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to investin R&D =9 more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity
Slide 34: Management and Board of Directors
08 Management and Board of Directors
Slide 35: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - Board of Directors Management team @ Akshay Bansarilal ® Shiven Akshay © Naresh Suryakant Shah Ganesh Vimalendu Kumar Singh @ Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President - Research and
Slide 36: Management team and independent board of directors (cont'd)
Experienced and visionary management team backed by independent oard of Directors (cont’d) Management team (cont’ Independent board of directors Sweta Poddar ®Girish Paman ©® Preeti Gautam 6 Divya Sameer Company Secretary and Vanvari Mehta Momaya Compliance Officer Independent Director Independent D
Slide 37: Investment Rationale
09 ’4 Investment s d Rationale
Slide 38: Investment Rationale
Investment Rationale Large manufacturer of contrast Presence in niche categories media intermediates in India with high barriers to entry Long-standing relationships and Strong product development and multi-year contracts with multi- 88 process optimization capabilities national customers with a foc
Slide 39: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONSAT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@bluejethealthcare.com 400705, Maharashtra, India NSE: BLUE